Denali Therapeutics (DNLI) Common Equity (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Common Equity of $926.1 million for Q1 2026, down 17.51% year-over-year from $1.1 billion in Q1 2025, and down 8.65% quarter-over-quarter from $1.0 billion in Q4 2025.
Denali Therapeutics (DNLI) Common Equity (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Common Equity for 10 consecutive years, with $926.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 17.51% year-over-year to $926.1 million; the TTM figure through Mar 2026 stood at $926.1 million (down 17.51% YoY), while the FY2025 annual figure was $1.0 billion, down 17.56% from the prior year.
- Common Equity retreated to $926.1 million in Q1 2026 per DNLI's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Common Equity topped out at $1.5 billion in Q1 2024 and bottomed at $1.8 million in Q3 2025.
- Historically, Common Equity has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2023.
- Annual changes were most pronounced in 2024 — Common Equity surged 50.56% — and 2025, when it slumped 99.86%.
- Denali Therapeutics' Common Equity stood at $1.0 billion in 2022, then dropped by 1.1% to $1.0 billion in 2023, then advanced by 19.28% to $1.2 billion in 2024, then decreased by 17.56% to $1.0 billion in 2025, then retreated by 8.65% to $926.1 million in 2026.
- Business Quant data shows DNLI's Common Equity at $926.1 million in Q1 2026, $1.0 billion in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 835.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 835.18 Mn |
| Mar 31, 2026 | 926.10 Mn |
| Dec 31, 2025 | 1.01 Bn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 1.12 Bn |
| Dec 31, 2024 | 1.23 Bn |
| Sep 30, 2024 | 1.32 Bn |
| Jun 30, 2024 | 1.39 Bn |
| Mar 31, 2024 | 1.46 Bn |
| Dec 31, 2023 | 1.03 Bn |
| Sep 30, 2023 | 1.12 Bn |
| Jun 30, 2023 | 1.19 Bn |
| Mar 31, 2023 | 966.71 Mn |
| Dec 31, 2022 | 1.04 Bn |
| Sep 30, 2022 | 811.30 Mn |
| Jun 30, 2022 | 884.45 Mn |
| Mar 31, 2022 | 917.93 Mn |
| Dec 31, 2021 | 962.29 Mn |
| Sep 30, 2021 | 1.01 Bn |